NCT03851705 - A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2019

Primary Completion Date

March 2, 2020

Study Completion Date

September 9, 2021

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

DRUG

Inclisiran Sodium for injection

Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.

DRUG

Placebo

Sterile normal saline (0.9% sodium chloride in water for injection)

DRUG

Placebos

Sterile normal saline (0.9% sodium chloride in water for injection)

Trial Locations (13)

2193

(50027-001) Johannesburg Hospital, Johannesburg

11000

(50381-001) Clinical Center of Serbia, Belgrade

11217

(50886-001) Taipei Veterans General Hospital, Taipei

34093

(50090-003) Istanbul University, Istanbul

35040

(50090-001) Ege Universitesi, Izmir

76018

"(50380-002) IMunicipal Non-commercial Enterprise Ivano-Frankivsk Regional Clinical Cardiology Center Ivano-Frankivsk Regional Council", Ivano-Frankivsk

91120

(50972-001) Hadassah Hospital Lipid Research Ein Kerem, Jerusalem

121552

(50007-003) National Medical Research Centre of Cardiology, Moscow

193079

(50007-002) Hospital for War Veterans, Saint Petersburg

650002

(50007-001) Research Institute of Complex Issues of Cardiovascular Diseases, Kemerovo

Unknown

(50852-001) Queen Mary Hospital, Hong Kong

06010

(50090-002) University of Health Sciences, Etlik

03680

(50380-001) National Scientific Center, Kyiv